Special Situations Investing With HART
Thu, Jun. 23, 11:00 AM
Thu, May 12, 7:35 AM
Thu, Mar. 31, 8:24 AM| Thu, Mar. 31, 8:24 AM
Fri, Mar. 18, 6:37 AM
- Harvard Apparatus (HART) Q4 results: Revenues: $8M (-82.2%); Operating Expense: $2.2M (-24.1%); Net Loss: ($2.3M) (+17.9%); Loss Per Share: ($0.17) (+52.8%).
- FY2015 results: Revenues: $0.1M (+11.1%); Operating Expense: $11.7M (+5.4%); Net Loss: ($11.7M) (-5.4%); Loss Per Share: ($1.05) (+25.5%); Quick Assets: $7.5M (+41.5%).
- No guidance given.
Thu, Mar. 17, 4:24 PM
Thu, Jan. 14, 12:46 PM
Dec. 1, 2015, 9:22 AM
Nov. 30, 2015, 12:49 PM
Nov. 27, 2015, 1:03 PM
- Nano cap Harvard Apparatus Regenerative Technology (HART +25.4%) jumps on triple normal volume. Shares are up almost four-fold sine November 11 as investors take positions ahead of a presentation by CEO Jim McGorry at an investor event in Los Angeles on Tuesday, December 1.
- Before the rally, shares had lost ~95% of their value on diminished prospects for the company's regenerated tracheas.
- The company generated some recent buzz with its report of clear evidence of esophageal tissue regeneration in animal studies based on its second generation bioengineered platform. The company plans to file an IND with the FDA in 2016 and aims to commence compassionate use procedures in humans sometime in 2016.
- Previously: Harvard Apparatus backs out of Russia (Nov. 26, 2014)
- Previously: HART up 34% on exoneration of misconduct by famed trachea transplant surgeon (Aug. 31)
- Previously: HART gets delisting warning from Nasdaq over share price (Nov. 10)
Nov. 27, 2015, 12:37 PM
Nov. 19, 2015, 12:44 PM
Nov. 19, 2015, 9:14 AM
Nov. 12, 2015, 4:52 PM
- Harvard Apparatus (NASDAQ:HART): Q3 EPS of -$0.19
- Shares -0.7%.
Nov. 10, 2015, 5:03 PM
- Nasdaq has sent Harvard Apparatus Regenerative Technology (HART -1.6%) a delisting warning after the company's share price missed the $1 closing bid requirement for 30 business days.
- HART will have until May 2 to regain compliance, by raising the closing bid over $1 for at least 10 straight business days.
- CEO Jim McGorry says that after spending the early part of his tenure on strategy, he can now focus on investor outreach and putting the company back in compliance.
Aug. 31, 2015, 1:07 PM
- Thinly traded nano cap Harvard Apparatus Regenerative Technology (HART +33.7%) is up on almost an 8x surge in volume, albeit on turnover of less than 1M shares, in response to the announcement that Karolinska Institute's inquiry into alleged misconduct by visiting professor Paolo Macchiarini cleared him of all charges regarding his reporting of the status of three patients (two who died) who received a replacement trachea implanted by him. In May, an independent investigator accused Macchiarini of misrepresenting key aspects of papers describing the surgical procedures which misled readers into thinking the procedures were more successful than they actually were. Certain data in the papers could not be found in the medical records, for example.
- Krolinska's probe did identify "certain circumstances" where the surgeon's work did not meet the university's high quality standards in every respect. He may have to submit amendments on several publications as a result. Also, allegations that he failed to get proper consents from patients before the operations are still being investigated.
- Macchiarini's problems shut down the clinical development of regenerated replacement tracheas, which were supplied by HART.
Aug. 31, 2015, 12:47 PM
Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage regenerative medicine company. It is engaged in the development and commercialization of devices for use by clinicians and researchers in the field of regenerative medicine and also develop instrumentation to tissue engineering... More
Country: United States
Other News & PR